Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!
Pfizer Inc. (NYSE: PFE) stock was trading slightly higher by 0.4 percent early Wednesday morning after the global pharmaceutical giant announced top-line results from a phase 3 study. The company said the trial of its Tanezumab for the treatment of osteoarthritis pain met all three co-primary endpoints.
Morgan Stanley (NYSE: MS) gained nearly 3 percent after reporting its second-quarter results. The banking giant said it earned $1.30 per share in the second quarter on revenue of $10.6 billion versus expectations of $1.11 per share and $10.1 billion.
Catalyst Biosciences Inc (NASDAQ: CBIO) was trading higher by 8 percent although the stock was seen earlier higher by more than 35 percent after reporting encouraging clinical data. The clinical-stage biopharmaceutical company reported positive interim data from a phase 2/3 study of its marzeptacog therapy supports the goal of significantly reducing annualized bleed rates with daily subcutaneous injections of marzeptacog alfa.
Adaptimmune Therapeutics PLC - ADR (NASDAQ: ADAP) gained more than 3 percent after reporting an encouraging update from a study. The T-cell therapy that focuses on treating cancer announced favorable review of safety data from the second dose cohort of patients who received the company's SPEAR T-cells.
Precipio Inc (NASDAQ: PRPO) spiked more than 65 percent after announcing preliminary second-quarter results. The specialty cancer diagnostics company said on a preliminary basis second quarter revenue rose 213 percent from $260,000 a year ago to $815,000.
28 Stocks Moving In Wednesday's Pre-Market Session
A Peek Into The Markets: US Stock Futures Flat; Morgan Stanley Earnings In Focus
See more from Benzinga
- With Cost Reductions Pushed Back To 2020, William Blair Downgrades Gogo
- Cannabis Producer Aphria's Latin American Expansion: What You Need To Know
- Wall Street's Reaction To Netflix's Q2 Earnings Report
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.